Clinical Trials in Massachusetts

Showing 1061-1080 of 15,316 trials

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Dystrophic Epidermolysis Bullosa

Castle Creek Biosciences, LLC.32 participantsStarted Mar 2025

Redwood City, California, United States • Santa Margarita, California, United States • Aurora, Colorado, United States +1 more locations

RECRUITINGPhase 326 miles

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

Primary IgA Nephropathy

Hoffmann-La Roche428 participantsStarted Aug 2023

Alabaster, Alabama, United States • Birmingham, Alabama, United States • Surprise, Arizona, United States +197 more locations

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Find Trials by Condition in Massachusetts

Elranatamab in R/R Multiple Myeloma

Innovating CBT-I for Cancer Survivors: An Optimization Trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Stepped Care for Posttraumatic Stress Disorder Study

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

Odronextamab in Low Tumor Volume Advanced FL

Advanta VXT and Flixene PMCF Registry

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)